After AstraZeneca reportedly rebuffed Pfizer's huge acquisition offer, we look into what makes the former's pipeline attractive to Pfizer and investors.
Dan Carroll, The Motley Fool, The Motley Fool
Thu, 04/24/2014 - 6:30am
After AstraZeneca reportedly rebuffed Pfizer's huge acquisition offer, we look into what makes the former's pipeline attractive to Pfizer and investors.